Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

IFPMA

- PMLiVE

Cubist gets green light from FDA for new antibiotic Sivextro

First drug approved under qualified infectious disease product framework

- PMLiVE

FDA fast-tracks new AstraZeneca antibiotic

Speeds up review period for AZD0914 in gonorrhoea

- PMLiVE

IFPMA issues psoriasis call to action

Pharma industry body plans to raise awareness of disease

Sanofi reception

Sanofi forms antibiotic research partnership

Will team up with Germany’s Fraunhofer-Gesellschaft to develop naturally-derived substances

- PMLiVE

Cell wall inhibitors for bacterial infections

There are limited pipeline prospects to address this significant health issue

- PMLiVE

Cubist posts positive phase III antibiotic data

CXA-201 on track for 2014 filings

- PMLiVE

IFPMA joins campaign against fake medicines

Pharma body teams up with other global health organisations

- PMLiVE

AZ strikes antibiotic deal with Singapore research unit

Deal with A*STAR to tackle antimicrobial resistance

Roche - Basel

Roche signs €400m superbug deal

Buys rights to investigational antibiotic from Polyphor

- PMLiVE

UK to improve commercial viability of antibiotic research

Government unveils new research incentives as part of antimicrobial resistance strategy

- PMLiVE

GSK awarded $200m by US government for antibiotic research

Follows state-supported schemes in Europe to combat resistance to antibiotics

- PMLiVE

UK says pharma needs incentives for antimicrobial drug research

Chief medical officer calls for greater risk-sharing between public and private sector

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links